These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24019001)

  • 1. Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Yoshihara HA; Danforth OM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Nat Commun; 2013; 4():2429. PubMed ID: 24019001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
    Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
    Chen R; Nishimura MC; Kharbanda S; Peale F; Deng Y; Daemen A; Forrest WF; Kwong M; Hedehus M; Hatzivassiliou G; Friedman LS; Phillips HS
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14217-22. PubMed ID: 25225364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
    Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
    Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
    Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
    Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.